Navigation Links
Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Ventrus Biosciences, Inc.
Date:5/10/2013

Ib studies in Germany as evidence of VEN 309's efficacy and as support for their claims that FDA approval would be achieved. These false and misleading statements artificially inflated, maintained, and increased the price of Ventrus' common stock, reaching a high of $20.25 during the Class Period.

On June 25, 2012, Ventrus issued a press release announcing that VEN 309 failed its Phase III trial before the FDA, and that the Company would abandon further development of VEN 309, including any further attempt to obtain FDA approval. In response to this news, the price of Ventrus common stock plummeted over 50% -- to $5.02 per share on June 25, 2012, resulting in millions of dollars in damages to investors.

Plaintiffs seek to recover damages on behalf of all Class members who invested in Ventrus securities during the Class Period.  If you invested in Ventrus securities as described above during the Class Period, and either lost money on the transaction or still hold the stock, you may wish to join in this action to serve as lead plaintiff.  In order to do so, you must meet certain requirements set forth in the applicable law and file appropriate papers no later than July 8, 2013.

A "lead plaintiff" is a representative party that acts on behalf of other class members in directing the litigation.  In order to be appointed lead plaintiff, the court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class.  Under certain circumstances, one or more class members may together serve as lead plaintiff.  Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff.  You may retain Bernstein Liebhard LLP, or other counsel of your choice, to serve as your counsel in this action.

If you are interested in discussing your rights as a Ventrus
'/>"/>

SOURCE Bernstein Liebhard LLP
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Bernstein Liebhard LLP Announces That A Securities Class Action Has Been Filed Against Aveo Pharmaceutical, Inc.
2. The law firms of Bernstein Litowitz Berger & Grossmann LLP and Labaton Sucharow LLP announce pendency of class action in In re Schering-Plough Corporation / ENHANCE Securities Litigation
3. Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Abiomed, Inc.
4. Par Pharmaceutical Companies, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By TPG
5. Amylin Pharmaceuticals, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Bristol-Myers Squibb Company
6. Watson to Present at the Sanford C. Bernstein 28th Annual Strategic Decisions Conference
7. Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma
8. Echo Therapeutics Announces First Quarter 2013 Financial Results
9. Life Care Medical Devices Ltd Announces Addition Of Dublin, Ireland Based European Subsidiary
10. Creabilis Announces Headline Results of its Phase 2b Trial of Topical TrkA Kinase Inhibitor CT327
11. Omeros Announces $16.2 Million Registered Direct Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 This ... for molecular imaging informatics solutions including nuclear imaging ... and comparison. The study assesses the size of ... 2010 and 2013, and projects future growth based ... as the dynamics taking place in the broader ...
(Date:9/30/2014)... -- Decision Resources Group finds that the markets for peripheral ... Russia , India ... see robust expansion as these economies expand and as ... revenues will be somewhat impeded by poor distribution of ... and demand for low-cost products, the market will ultimately ...
(Date:9/30/2014)... Sciences, Inc. (NASDAQ: ALIM ) (Alimera), a ... commercialization of prescription ophthalmic pharmaceuticals, announced today that it ... Growth Capital, Inc. (NYSE: HTGC ) (Hercules). ... the Loan and Security Agreement that Alimera,s subsidiary in ... Limited, entered into with Hercules in April of this ...
Breaking Medicine Technology:Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2
... and LOS ANGELES , May 10 ... "Company" or,"China Yongxin"), one of the leading health products company ... 2010 , the Company,s subsidiary, Changchun,Yongxin Dirui Medical Co. Inc. ... for Jilin province of China . According,to ...
... May 10 /PRNewswire-Asia/ -- On April 11, ... with Beijing Un-Assegai Technical &,Trade Co. Ltd. (hereinafter referred to ... China , as claimant and U.S. Abbott,Laboratories (Abbott U.S.; NYSE: ... the,China International Economic and Trade Arbitration Commission (CIETAC), which,has recently ...
Cached Medicine Technology:China Yongxin Pharmaceuticals is Selected as one of the Qualified Pharmaceutical Distributors for Jilin Province 2China Yongxin Pharmaceuticals is Selected as one of the Qualified Pharmaceutical Distributors for Jilin Province 3Assegai Wins Big Settlement Against ABBOTT's Subsidiary 2
(Date:10/1/2014)... Chino Hills, CA (PRWEB) October 01, 2014 ... the internationally-franchised Fit Body Boot Camp fitness boot camps, ... selling personal training , with sold out business ... a stint as marketing consultant to a recent Spike ... looming, Keuilian says that now is the time for ...
(Date:10/1/2014)... FARMINGTON, Conn. (PRWEB) October 01, 2014 ... its company, including a redefined mission and visual ... the power of partnering with them to create ... more agile brand that focuses on empowering customers ... benefits communications. , The crown jewel of the ...
(Date:10/1/2014)... October 01, 2014 Innovations announces the ... to broadcast on Monday, October 20, 2014 at 7:30 ... Innovations will go behind the scenes to learn about ... segment will explore the practical help and information Break ... teaches the warning signs of abuse, how to navigate ...
(Date:10/1/2014)... On Sept. 9, Chapín Coffee was ... Martha Stewart American Made Awards (MSAMAs), an annual competition ... in the fields of crafts, design, food and style. ... finalist in the MSAMAs, which celebrates entrepreneurs and artisans ... local communities and changing the way we shop, work ...
(Date:10/1/2014)... October 01, 2014 Dr. Saj Jivraj, ... and prosthodontists, is traveling to Chennai, India, tomorrow to ... Oct. 2 and 3. , Dr. Jivraj is founder ... and Oxnard, Calif., and one of the world’s foremost ... and replacement. He is speaking to the Indian Society ...
Breaking Medicine News(10 mins):Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:Chicago Coffee Start-up Makes a Big Impact, Earns National Recognition 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 3Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 4Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 5
... Association of Retired Xerox Employees, Inc. (ARXE) has retained ... R. Pfalzgraf, Jr., Esq., and Danielle Shainbrown, Esq.) and ... action against Xerox Corporation, in an effort to maintain ... retirees. , Beginning in 2010, nearly 25 percent of ...
... Sept. 30 Connectyx Technologies Holding Group Inc. (Pink Sheets: ... York, NY as its independent registered public accountant for the ... be provided include auditing and preparation for filing Form 10 ... for Connectyx in order to become a Fully Reporting Company ...
... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) today announced ... SR/zonisamide SR), the Company,s second late stage investigational combination ... efficacy endpoint by demonstrating statistically significantly greater weight loss ... The Company plans to meet with the U.S. ...
... Halloween just around the corner, health-conscious adults and trick-or-treaters ... other snacks that are starting to hit store shelves. ... alternative treat that won,t derail their healthy lifestyles need ... Milk®. , Tiger,s Milk has delivered essential proteins, ...
... , CLAREMONT, Calif., Sept. 30 ... Program (PBPM), scheduled to begin in January 2010, for those ... interested in enhancing their skills before applying to medical school. ... a career as a medical professional," says Sheldon M. Schuster, ...
... BEIJING, Sept. 30 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: ... China, announced today that,Sinovac has received its second purchase ... Industry and Information Technology of the People,s,Republic of China ... is required to produce an additional 3 million doses ...
Cached Medicine News:Health News:Association of Retired Xerox Employees Initiate Legal Proceedings Against Xerox Corporation 2Health News:Connectyx Technologies Retained the Marcum Group in New York as its Independent Registered Public Accountant for the Purpose of Becoming a Fully Reporting Company 2Health News:Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients 2Health News:Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients 3Health News:Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients 4Health News:Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients 5Health News:Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients 6Health News:Have a Healthier Halloween with Tiger's Milk(R) 2Health News:KGI Establishes Post Baccalaureate Premedical Program 2Health News:Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government 2Health News:Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government 3
... Philip's EASITrak 12 gives you the detailed ... treatment decisions for your patients with palpitations, ... with the EASI Lead System, this transtelephonic ... to capture a derived 12-lead ECG. Comfortable ...
... Viewer Phonocardiogram (PCG). The ZAC-Viewer is ... to record, condition, display and print heart ... The product acquires and displays the recorded ... sites, and allows user-selectable filtering of each ...
... with the challenge of,controlling costs while ... patient data,management is critical. INFINITY modular,patient ... important clinical information,wherever you are in ... concept,makes your job easier. You can ...
... system is a combination of a Siemens SOMATOM ... AXIOM Multistar angiography unit. Both systems use the ... between floating DSA position and fixed CT position. ... the park position. When it is nesessary to ...
Medicine Products: